Julie Talavera, MD
Endocrinology, Diabetes & Metabolism · Metairie, LANPI 1124268008
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 57 manufacturers reported payments, led by Novo Nordisk at 54.6% of the total. Reporting peaked in 2019 at $17,132 and has fallen 68.8% since, to $5,350 in 2025.
Across 1,194 payments — averaging $41.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$27K
- Abbott$6K
- Lilly USA, LLC$2K
- Amgen$2K
- AstraZeneca$2K
- Dexcom, Inc.$1K
- plus $10K from 51 others
What the payments were for
- Consulting fees$2,1304%
- Speaking & faculty fees$24,71750%
- Travel & lodging$8062%
- Food & beverage$21,53044%
- Education$640%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$13,816
- RYBELSUS$5,834
- Tresiba$4,023
- FreeStyle Libre Pro$3,760
- iLet Bionic Pancreas$1,053
- FREESTYLE LIBRE 3$432
- DEXCOM G6 TRANSMITTER$247
- Korlym$225
- Omnipod$141
- Prolia$125
- Wegovy$125
- TEPEZZA$125
- FARXIGA$119
- EVENITY$103
How this compares
$49,366 in reported general payments places this provider in the 85th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 429 | $562,637 |
| RecorlevLevoketoconazole | 12 | $426,702 |
| MounjaroTirzepatide | 259 | $285,917 |
| Tresiba Flextouch U-100Insulin Degludec | 307 | $186,666 |
| JardianceEmpagliflozin | 164 | $159,178 |
| FarxigaDapagliflozin Propanediol | 128 | $106,151 |
| ProliaDenosumab | 56 | $97,743 |
| JanuviaSitagliptin Phosphate | 114 | $97,584 |
| TrulicityDulaglutide | 58 | $82,053 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 69 | $76,026 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 72 | $75,407 |
| TymlosAbaloparatide | 25 | $65,779 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 87 | $61,989 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $52,857 |
| Novolog FlexpenInsulin Aspart | 242 | $48,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Fiasp | $26,944 | $602,876538 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $1,024 | $426,70212 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,707 | $389,361376 claims |
| Boehringer IngelheimJardiance, Tradjenta | $639 | $179,502194 claims |
| MerckJanuvia, Janumet, Janumet Xr | $270 | $130,922167 claims |
| AstraZenecaFarxiga | $1,525 | $106,151128 claims |
| AmgenProlia | $1,630 | $97,74356 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $794 | $79,11899 claims |
| Radius Health, Inc.Tymlos | $495 | $65,77925 claims |
| BayerKerendia | $511 | $27,13515 claims |
| Johnson & JohnsonInvokana | $203 | $21,77822 claims |
| AbbVieSynthroid, Armour Thyroid | $517 | $18,102332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Metairie
- Tuan Huy TranMetairie$34K
- Jonathan WiseMetairie$20K
- Joseph MurrayMetairie$7K
- Miguel RiveraMetairie$7K
- Escipion PedrozaMetairie$2K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.